anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An antiperspirant cosmetic composition comprising, by weight of the composition (a) 10.0 to 75.0 wt% of at least one hydrogenated polyisobutene of the formula H-[CH2-C(CH3)2]n-H wherein n is 4 or 5; (b) 7.0 to 40.0 wt% of at least one aluminium salts antiperspirant active ingredient; and c) 10.0 to 45.0 wt% of at least one C8-16 triglyceride, is provided. The composition may further comprise 5.0 to 40.0 wt% PPG-14 butyl ether; 5 to 40 wt% of C12-15 alkyl benzoate and/or 5 to 40 wt% phenoxyethyl caprylate. The composition may further comprise 10 to 30 wt% of C16-20 fatty alcohol(s). The composition may further comprise 0.5 to 15 wt% of at least one cosmetic wax, preferably selected from myristoyl myristate, hydrogenated castor oil or mixtures thereof. The composition is preferably free of intentionally added silicone oil(s). The antiperspirant active ingredient may comprise at least one organic or inorganic aluminium salt or an organic or inorganic aluminium-zirconium salt; preferably an activated aluminium chlorohydrate. The C8-16 triglyceride may be caprylic/capric triglyceride. The antiperspirant compositions have high efficacy, good stability and a dry skin feel, and can be formulated free of silicone oils, which gives them better biodegradability.
The inventors have discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKβ8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CKβ8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CKβ8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. 
     This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.
PURPOSE: To provide a freeze-dried biomatrix which is prepd. by compounding natural polysaccharides or denatured polysaccharides and further, water at specific ratios, has a skin moistening effect, less consumes active substances and is suitable for carrier materials, etc., of the active substances of medicines and cosmetics. CONSTITUTION: This biomatrix is obtd. by freeze drying the aq. polysaccharide soln. Namely, the biomatrix contains 10 to 80 wt.% natural polysaccharides and 20 to 90 wt.% denatured polysaccharides. More preferably the biomatrix contains the natural polysaccharides and/or the denatured polysaccharides at 25 to 70 wt.% and the water at 5 to 15 wt.%, more particularly 10 wt.%. The natural polysaccharides are preferably pectin, alginate, carrageenin, agar, Carob (Ceratonia siliqua. L.) flour, etc., and the denatured polysaccharides are film formable binders, such as carboxymethyl cellulose. Fibrous components for improving the stability at dry and/or cosmetic or medicine active substances may be incorporated into this matrix. The matrix does not necessitate the use of skin stimulative substances, such as antiseptics, dyestuff and perfume, and is thus advantageous.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis was suspected to be pleural metastasis, osimertinib treatment was continued until disease progression. We analyzed the evolution of genomic alterations and the levels of AXL using tumor specimens obtained by repeated biopsies during the course of treatment: initial diagnosis, operation, and disease progression. Genetic alterations detected at the three time points were dramatically changed and showed reductions in numbers, while EGFR-L858R mutations were detected in all samples tested in both patients. Immunohistochemical expression of AXL remained positive from the beginning of analysis to disease progression. Clonal evolution under oncogenesis is related to gradual accumulation of genomic alterations during tumor growth. However, our case series revealed that volume reduction procedures may cause this phenomenon. Therefore, identification of intrinsic drug-resistant cells in tumors may be as important as detection of acquired genetic alterations.
Hepatic metastasis is the most common in rectal cancer, and patients with resectable hepatic metastasis have better survival. Pelvic radiotherapy has become a key component of multidisciplinary management of rectal cancer with hepatic metastasis. For patients with unresectable hepatic metastasis, palliative radiotherapy to the primary lesion can reduce the risk of bleeding and obstruction and thus improve the quality of life. For patients with resectable hepatic metastasis, pelvic radiotherapy can effectively reduce the local recurrence rate, help some patients avoid surgery and improve their quality of life, and even improve the overall survival. At present, there is no consensus on the standardized treatment mode of pelvic radiotherapy for rectal cancer patients with hepatic metastasis, and it has become a hotspot for research on how to select the population benefiting from radiotherapy, how to optimize multidisciplinary collaboration and radiotherapy plans (long-course radiotherapy versus short-course radiotherapy) and how to preserve organs. This article reviews the research progress in pelvic radiotherapy for rectal cancer with hepatic metastasis in recent years, and provides ideas for individualized pelvic radiotherapy for rectal cancer with hepatic metastasis.
These are characterized by excitation and/or depression. Restlessness, anxiety, dizziness, tinnitus, blurred vision, or tremors may occur, possibly proceeding to convulsions. However, excitement may be transient or absent, with depression being the first manifestation of an adverse reaction. This may quickly be followed by drowsiness merging into unconsciousness and respiratory arrest. Other central nervous system effects may be nausea, vomiting, chills, and constriction of the pupils. 

The incidence of convulsions associated with the use of local anesthetics varies with the procedure used and the total dose administered. In a survey of studies of epidural anesthesia, overt toxicity progressing to convulsions occurred in approximately 0.1% of local anesthetic administrations.
Study treatment is given in 4-week time periods called cycles. Patients will receive ST-9090 once weekly for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.

During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen.
Background: Delayed-onset muscle soreness (DOMS) is an acute micro-trauma or inflammatory response experienced in the most runners; and, it concurrently impairs athletic performance and may increase risk of sports injury. Alleviating the symptoms of DOMS strategies are various; however, the specific recovery way remains unconcluded. Furthermore, few studies have investigated that the effects of vibrating roller on alleviating the symptoms of DOMS, and understand the biochemical changes in response to recovery of athletic performance. Therefore, this study hypothesizes that vibration rolling (VR) could provide self-myofascia release. Meanwhile, vibration exercise could tramsit vibration to speific muscle groups to decrease inflammation in corresponding to reduce muscular pain. Therefore, it could offer positve effects including improvements of flexability, muscle stiffness, visual analog scale (VAS) for pain, jmup, and dynmaic balance. Purpose: To investigate VR, non-vibration rolling (NVR), and static stretching for DOMS on physiological changes and recovery of athletic performance in runners. Methods: Thirty healthy and recreationally adult runners will be voluntarily recruited in the experiment. Participant will be induced DOMS on the treadmill exercise firstly. Next, participants will be matched up and randomly assigned to the VR group, NVR group or static stretching group treatment. Each participant will be instructed to 20-minutes treatment on bilateral muscles including gluteus, anterior, and posterior thighs as well as anterior, and posterior legs. All subjects will receive blood analysis (leukocyte, lymphocyte, creatine kinase, c-reactive protein, interleukin-6) and perform flexibility muscular stiffness, VAS for pain, counter movement jump, Y balance tests on lower limb before exercise and after 24hour and 48 hour interventions. Expected outcomes: VR could effectively alleviate the symptoms of DOMS including decreasing inflammatory biochemical values, decreasing muscular stiffness, reducing muscular pain, and increasing flexibility and jump ability as well as improving dynamic balance on lower limb. This data may provide in alleviating the symptoms of DOMS to healthy populations, athletes, and medical team members.

Key Words: Delayed-onset muscle soreness, vibration therapy, foam roller, stretching exercise, recovery, performance
Mixtures of fructose and lactose are useful for reducing caloric intake and glycemic index for individuals who are overweight, glucose-impaired, diabetic, or who just consume too large a fraction of their calories from "added sugars". The fructose/lactose sweetener is included in the daily diet as a one- for-one replacement for "added sugars" in various edible formulations without sacrificing quality of taste. Sucrose can be used as a replacement for all or part of the fructose in the claimed sweetener to increase sweetness or improve certain functional properties without substantially changing caloric value. The claimed mixtures of fully-caloric sugars work synergistically to reduce available calories and blood sugar concentration. Specifically, fructose interferes strongly with normal small-intestinal absorption of lactose and interferes moderately with sucrose absorption, while lactose interferes with normal small-intestinal absorption of both sucrose and starch. Unabsorbed di- and oligosaccharides pass into the colon and cause increased growth of healthful bacteria, making the new sweetener useful as a prebiotic. No gastrointestinal symptoms of sugar intolerance were observed when the claimed sugar mixtures were ingested at normal dietary levels.
BACKGROUND: Heart failure (HF) and colorectal cancer are significant public health concerns with substantial morbidity and mortality. Previous studies have indicated a close association between HF and various tumors, including colorectal cancer. Further understanding the potential causal relationship between them could provide insights into their shared pathophysiological mechanisms and inform strategies for prevention and treatment.
METHODS: This study employed a bidirectional Mendelian randomization (MR) approach using genetic variants from large genome-wide association studies (GWAS) as instrumental variables (IVs). The inverse-variance weighted (IVW) method was employed for the MR analysis. Meta-analyses of IVW results from discovery and validation cohorts were performed to enhance the power of detecting causal effects. Sensitivity analyses, including heterogeneity analysis and tests for horizontal pleiotropy, were conducted to test the robustness of the conclusions.
RESULTS: Results from the discovery cohort suggest HF is associated with an approximately 30% increased risk of colorectal cancer (OR 1.32, 95% CI 1.03-1.69, P=0.025), although this finding did not reach statistical significance in the validation cohort (OR 1.19, 95% CI 0.97-1.46, P=0.090). However, meta-analysis supports HF as a potential risk factor for colorectal cancer (Pooled OR 1.24, 95% CI 1.06-1.25, P=0.007). Reverse MR analysis found no evidence of colorectal cancer increasing HF risk (Pooled OR 1.03, 95% CI 0.99-1.07, P=0.121). Sensitivity analyses (all P>0.05) indicate robustness against heterogeneity and horizontal pleiotropy.
CONCLUSION: This comprehensive bidirectional MR study provides genetic evidence supporting a causal link between HF and colorectal cancer. The insights gained enhance understanding of their interconnectedness and may guide future research and clinical practices aimed at mitigating their risks through targeted interventions.
This prospective study will include approximately 25 patients with open-angle glaucoma who will undergo TCNR of trabeculectomy bleb by a glaucoma specialist at Northwestern Medicine. These patients will have a history of glaucoma and failed trabeculectomy bleb (as evidenced by clinical features and elevated IOP). During routine clinic visit, the patient will undergo lit lamp grading of bleb by Indiana Bleb Appearance Grading Score (IBAGS). Subjects who agree to participate and provide written informed consent will undergo AS-OCT imaging (Spectralis OCT, Heidelberg) of the bleb. During their operation, the Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), a commercially available device will be utilized to visualize and evaluate the morphology of the trabeculectomy bleb at the start and conclusion of the case.
The invention relates to cosmetic products especially skin cleansing agents characterized in that they contain (a) 20 to 80 wt. % ethoxylated partial glyceride and optional (b) 0.1 to 80 wt. % oil bodies with the condition that optional amounts of water and usual auxiliary and addition agents supplement the mass up to 100 wt. %. The products are transparent and spread easily and smoothly when applied to the skin. During application, said agents make the skin feel pleasant and fresh and are especially suitable for removing decorative cosmetics such as make-up.
Patients with newly diagnosed high-risk Grade II or III astrocytoma must undergo maximal safe resection (biopsy alone may be eligible) and chemoradiotherapy: concomitant 75mg/m2 daily temozolomide with 80% prescribed dose completed and RT with minimal RT dose of 40 Gy delivered.

Within three weeks prior to beginning adjuvant temozolomide, all patients will undergo a Baseline contrast-enhanced MRI of the brain. Within two weeks prior to beginning adjuvant temozolomide, all patients will undergo baseline assessments. Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given. Patients will be seen and examined before each cycle of temozolomide. After a maximum of 12 cycles of adjuvant temozolomide, patients will be seen every 8 weeks. Brain MRI and QoL assessments will be performed every 8 weeks following the baseline MRI for the first 2 years then every 3 months thereafter until second progression (when TTFields treatment will be terminated).
Low back pain (LBP) is a common disorder that affects about 80% of adults at least once in a period of their life. 10% of low back pain becomes chronic and can affect the quality of life negatively and lead to disability. The STarT-Back-Tool was developed to identify people with poor prognosis, such as difficulty returning to work, loss of work force, disability. It has been reported that it would be beneficial to categorize patients according to their risk levels with this tool and plan treatment in primary care treatment centers. Being able to identify patients with a high probability of becoming chronic in the early period is very important to reduce or prevent disability that may occur. The aim of this study is to examine the effectiveness of StArt Back Tool test in determining prognosis and loss of workforce in patients presenting with low back pain complaints in the acute-subacute period and to examine the relationship between StArt Back Tool test and kinesophobia.
Aspects include receiving a document and classifying at least a subset of the document as having a first type of data. Features are extracted from the document. The extracting includes initiating processing of the at least a subset of the document by a first processing engine that was previously trained to extract features from the first type of data. The extracting also includes initiating processing of a remaining portion of the document not included in the at least a subset of the document by a second processing engine that was previously trained to extract features from a second type of data. The first type of data is different than the second type of data. Features are received from one or both of the first processing engine and the second processing engine. The received features are stored as features of the document.
In patients with hypovolemia or dehydration, pulse pressure variation can be increased by spontaneous forced inspiratory breathing. PVI is a noninvasive method of indicator of fluid responsiveness like purse pressure variation. We expected that the amount of change in PVI between at the time of entering operating room and after preoxygenation with forced inspiration method could be different depending on the patient's volume status.

After entering operating room, monitoring devices, anesthesia depth sensor, and Radical-7® Pulse CO-Oximeter® are attached. Patients rest for 5 minutes, and then baseline systolic blood pressure, diastolic blood pressure, mean blood pressure, and heart rate are collected every 1-minute. Pleth variability index (PVI), perfusion index (PI) are also measured continuously. For pre-oxygenation of anesthesia, take 8 deep breaths at flow 10 l/min of 100% oxygen for 1 minute with maximally forced inspiration. After that, for 2 minutes, patients breathe as usual while maintaining oxygen supply. until tracheal intubation or laryngeal mask insertion. Anesthesia is induced with target concentration infusion of 4.0 ng/ml of remifentanil and 4.0 ug/ml of propofol. When the patient loses consciousness, rocuronium 1.0 mg/kg is administrated and endotracheal tube or laryngeal mask is inserted 2 minutes after. PVI, PI, blood pressure, and heart rate are measured until tracheal intubation or laryngeal mask insertion. Anesthesia induction-related hypotension is defined as a decrease in mean arterial pressure below 60 mmHg at any timepoint from baseline parameter collection to until airway device insertion. The parameters are analyzed by comparing between groups with and without anesthesia induction-related hypotension.
PCT No. PCT/EP92/01793 Sec. 371 Date Mar. 18, 1994 Sec. 102(e) Date Mar. 18, 1994 PCT Filed Aug. 6, 1992 PCT Pub. No. WO93/02711 PCT Pub. Date Feb. 18, 1993.The present invention provides the use of a persistent  pi -system free radical for the manufacture of a contrast medium for use in magnetic resonance imaging, wherein the electron delocalising  pi -system of said radical comprises at least one homo or heterocyclic ring, said radical being other than the chloranil semiquinone anion radical or a trityl radical. Also provided are magnetic resonance imaging contrast media containing and methods using such radicals.
A large body of research has documented racial/ethnic disparities in childhood obesity in the United States (US) but less work has sought to understand differences within racial groups. Longitudinal studies are needed to describe BMI trajectories across development, particularly for Black children from immigrant families who have been underrepresented in childhood obesity research. The current study utilizes BMI data collected longitudinally from ages 5 to 8 years and growth mixture modeling to (1) identify and visualize growth patterns among Black children from primarily Caribbean immigrant families, and (2) to compare these patterns to growth trajectories among Black children from US-born families. First, we identified four classes or trajectories of growth for Black children from immigrant families. The largest trajectory (70% of the sample) maintained non-overweight throughout the study period. A second trajectory developed overweight by age 8 (25%). Two small trajectory groups demonstrated high rates of moderate and severe obesity-i.e., specifically, a trajectory of accelerated weight gain ending in moderate/severe obesity (3%), and a trajectory of early severe obesity with BMI decreasing slightly with age (2%). We identified a very similar four class/trajectory model among Black children from US-born families, and compared the model to the one for children from immigrant families using multi-group growth mixture modeling. We found that the patterns of growth did not differ significantly between the populations, with two notable exceptions. Among Black children from immigrant families, ∼ 5% were classified into the two heavier BMI trajectories, compared to ∼ 11% of children from US-born families. Additionally, among children with an accelerated weight gain trajectory, children from immigrant families had lower BMIs on average at each time point than children from US-born families. These findings describe the multiple trajectories of weight gain among Black children from immigrant families and demonstrate that although these trajectories are largely similar to those of Black children from US-born families, the differences provide some evidence for lower obesity risk among Black children from immigrant families compared to Black children from US-born families. As this study is the first to describe BMI trajectories for Black children from immigrant families across early and middle childhood, future work is needed to replicate these results and to explore differences in heavier weight trajectories between children from immigrant and US-born families.
The treatment arm will receive 6 week supply of daily Ensure protein drinks, while the control arm will be instructed to continue their current diet. This includes 2 weeks pre-operatively and 4 weeks post-operatively.